Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of RNA m6A methylation detection reagent in preparation of product for predicting breast cancer anti-HER2 treatment effect

A detection reagent, breast cancer technology, applied in the field of biomedicine, can solve the problems of lack of accurate prediction of treatment response and recurrence risk

Pending Publication Date: 2022-07-22
SUN YAT SEN UNIV CANCER CENT
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Third, enhanced expression of receptor tyrosine kinases (RTKs) leads to compensatory activation of alternative signaling pathways
More importantly, there is currently a lack of biomarkers that accurately predict treatment response and risk of relapse in patients after anti-HER2 therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RNA m6A methylation detection reagent in preparation of product for predicting breast cancer anti-HER2 treatment effect
  • Application of RNA m6A methylation detection reagent in preparation of product for predicting breast cancer anti-HER2 treatment effect
  • Application of RNA m6A methylation detection reagent in preparation of product for predicting breast cancer anti-HER2 treatment effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] 1. Cell Lines and Reagents

[0018] Human breast cancer cell lines (SKBR3, BT474 and AU565) were purchased from the American Type Culture Collection and cultured according to the manufacturer's instructions. rSKBR3, rBT474 and rAU565 cells were induced by selection by three months of 1 μM trastuzumab treatment. These obtained trastuzumab-resistant cell lines (rSKBR3, rBT474 and rAU565 cells) were continuously cultured in regular medium containing trastuzumab, which was withdrawn during the first four weeks of the experiment deal with. Cell lines were passaged for no more than six months and identified by STR analysis. Mycoplasma infection was not found in any of the cell lines. Trastuzumab was obtained from Roche (Basel, Switzerland).

[0019] 2. Dot Blot Analysis

[0020] First, the RNAs of the above-mentioned trastuzumab-sensitive human breast cancer cell lines and trastuzumab-resistant human breast cancer cell lines were extracted using Trizol, respectively. Is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of an RNA m6A methylation detection reagent in preparation of a product for predicting a breast cancer anti-HER2 treatment effect. It is found for the first time that the m6A methylation modification level of HER2 positive breast cancer fresh tissue RNA has a good clinical prediction value for the breast cancer anti-HER2 treatment effect. If the methylation level of RNA m6A is high, the breast cancer anti-HER2 treatment sensitivity is high; if the methylation level of RNA m6A is low, the breast cancer anti-HER2 treatment sensitivity is low. Whether the methylation level of RNA m6A in fresh tissues of a breast cancer patient is changed or not is detected, so that the sensitivity condition of the patient on the anti-HER2 drug is predicted. The invention provides a new treatment and prognosis prediction target for breast cancer anti-HER2 treatment, and provides a new target for improving breast cancer anti-HER2 drug resistance.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of a detection reagent for RNA m6A methylation level in the preparation of a product for predicting the curative effect of breast cancer anti-HER2 treatment. Background technique [0002] According to the latest global statistics, breast cancer has surpassed lung cancer as the most common malignancy worldwide, with an estimated 2.3 million new cases in 2020. Amplification and / or overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 14–30% of all breast cancer cases defined as HER2-positive breast cancer; this subtype is associated with poorer survival outcomes related. Trastuzumab (trade name Herceptin) is the first humanized anti-HER2 monoclonal antibody that significantly prolongs survival in patients with early-stage or metastatic HER2-positive breast cancer. Despite the remarkable efficacy of trastuzumab, the development of drug res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/154C12Q2600/118C12Q2600/106
Inventor 谢小明唐海林邹宇田刘鹏谢新华叶锋李星郑少全唐宇辉田文文谢锦东邓鑫霈曾艳
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com